Purpose: Bevacizumab, a humanized, antivascular endothelial growth factorA monoclonal antibody, has shown efficacy in a number of cancers. However, its use in metastatic breast cancer (MBC) remains controversial. Methods: A literature review using the PubMed database was performed to update the currently available clinical trials evidence on bevacizumab in the firstline treatment of breast cancer. In addition, the proceedings of selected oncology annual meetings were searched for relevant presentations. Results: This article reviews the available evidence for bevacizumab as firstline therapy for MBC and discusses its current and future applicability in the management of MBC. Three phase III trials (ECOG2100, AVADO, RIBBON1) demonstrated that the addition of bevacizumab to chemotherapy is welltolerated and improves progressionfree survival and objective response rates in the firstline setting. These findings were supported by a large clinical practicebased study (ATHENA) and a recent clinical trial in which bevacizumab added to paclitaxel showed notable activity in triple negative MBC. However, bevacizumab has thus far not demonstrated a significant benefit in overall survival. Conclusions: The addition of bevacizumab to chemotherapy is welltolerated and produces substantial improvements in overall response rate and progressionfree survival, compared with chemotherapy alone, in advanced HER2negative breast cancer. Nevertheless, it has thus far not demonstrated a significant benefit in overall survival. Whether prolongation of progressionfree survival is enough to consider bevacizumab efficacious is unclear. Based on the available clinical trials results, bevacizumab is a part of the complex therapeutic strategy of advanced HER2negative breast cancer.
Introduction
Breast cancer (BC) is recognized as a complex and heterogeneous disease due to the diversity of its molecular features, range of multiple morphologic subtypes, and the differences seen in response to therapy and patient outcomes (1) . Current treatment for metastatic BC (MBC) includes hormonal therapy or chemotherapy. Taxanes and anthracyclines are the most active chemotherapy agents in BC (1) . Furthermore, approaches combining antiangiogenic agents, such as bevacizumab, with standard chemotherapy have been shown in clinical trials to prolong prog ressionfree survival (PFS) without causing unacceptable toxicity. DOI: 10.5301/tj.5000555 
Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons
There is a firm basis to support the rationale of employing antiangiogenic agents in the treatment of cancer. It is welldocumented that organ growth and repair is dependent on angiogenesis, the physiologic process leading to the formation of new blood vessels. Disturbance of the tightly regulated physiologic balance underlying angiogenesis is an important factor in the development of a number of pathologic processes, such as inflammatory conditions, malignancies, and vascular and immune disorders (2) . Tumor growth and the development of metastatic disease is dependent on angiogenesis. Vascular endothelial growth factor (VEGF) is thought to play a critical role in tumor angiogenesis (3) by stimulating the proliferation and migration of vascular endothelial cells, inhibiting apoptosis and antigenpresenting dendritic cells, inducing extracellular matrix remodeling, and increasing vascular permeability and vasodilation (4) . Among various isoforms of VEGF, VEGFA has been demonstrated to be the most potent in determining vasodilation and tumor angiogenesis, and its function is mediated by binding to VEGF receptors 1 and 2 (VEGFR1 and VEGFR2) (5) .
A hypothesis generated by Folkman (6) in 1971 proposed that tumor progression could be prevented by interference with tumor angiogenesis, causing inhibition of new blood vessel formation and stimulating the loss of existing vessels. Furthermore, as proposed by Jain (7) , tumor vessels appear to be structurally and functionally abnormal and are tightly associated with stabilizing pericytes and less dependent than normal vessels on VEGF for survival. So, unlike the counterpart of embryogenically derived blood vessels, the vasculature of tumors is chaotic and poorly organized, with evidence of hyperpermeable, irregularly shaped, tortuous, dilated, and saccular blood vessels characterized by restricted blood flow (7) . Vascular endothelial growth factor inhibition causes these immature blood vessels to be "normalized." Thus, following antiVEGF therapy, a higher percentage of pericyteassociated blood vessels in the tumor vasculature are able to function more efficiently, at least transiently. The associated improvement in blood flow within the tumor enhances the delivery of cytotoxic chemotherapy (8) . Besides, antiangiogenic therapy results in the reduction of interstitial pressure and thereby facilitates tissue penetration of chemotherapy (9) . Consequently, VEGF blockade with bevacizumab or another antiangiogenic agent may enhance the antitumor effect of chemotherapy (5, 6) . Furthermore, levels of VEGF also affect response to endocrine therapy, regardless of steroid hormone receptor status.
In advanced BC, the presence of a high tumor VEGF level was found to be an independent marker predicting a poor response to firstline endocrine therapy (10) or to both firstline endocrine therapy (tamoxifen) and firstline chemotherapy (11) .
Bevacizumab (Genentech Inc., South San Francisco, CA, USA) is a humanized monoclonal antibody against all VEGFA isoforms, and it prevents the binding of VEGF to receptors on vascular endothelial cells, leading to the inhibition of angiogenesis and tumor growth. It has been shown to be effective in colorectal cancer, non-small-cell lung cancer, renal cell carcinoma, ovarian carcinoma, cervical cancer, and glioblastoma multiforme (1217). However, to date, in BC, bevacizumab has generated more controversies than any other targeted therapy.
In February 2008, the US Food and Drug Administration (FDA), based on promising results of the Eastern Cooperative Oncology Group (ECOG) 2100 trial (18) , granted accelerated approval to bevacizumab in combination with paclitaxel for the firstline treatment of HER2negative MBC. However, on July 20, 2010, the Oncologic Drugs Advisory Committee of the FDA's Center for Drug Evaluation and Research voted against the combination of bevacizumab with chemotherapy for the firstline treatment of MBC (19) . A definitive announcement by the FDA that revoked approval of bevacizumab for this indication followed (20) .
Bevacizumab is still approved in several countries as firstline treatment of advanced BC. European regulatory authorities came to a different conclusion than the FDA, and bevacizumab not only continues to be an accepted option for MBC in Europe but has been approved by the European Medicines Agency's Committee for Medicinal Products for Human Use in an extended indication: MBC in combination with capecitabine as firstline therapy when a taxane/anthracycline combination cannot be used.
The difference in the regulatory status of bevacizumab in the United States and Europe has been the subject of debate, and the regulatory authorities reached different conclusions regarding its clinical benefit. This article reviews the available data on the use of bevacizumab in the firstline treatment of MBC and examines these findings in the context of the FDA's revocation of its approval in the United States.
Methods
A literature search using the PubMed database identified Englishlanguage reports of clinical trials of bevacizumab in the firstline treatment of BC. In addition, the proceedings of the San Antonio Breast Cancer Symposium, European Society of Medical Oncology, and American Society of Clinical Oncology annual meetings were searched for presented abstracts using the following terms: bevacizumab and breast cancer or chemotherapy or efficacy or safety or cost. Each study was reviewed and phase III trials in patients with locally recurrent BC or MBC who had never been treated for metastatic disease and who received bevacizumab in combination with standard chemotherapy or broad communitybased population were evaluated ( Fig. 1 ).
Results
Three phase III trials tested the addition of bevacizumab to chemotherapy in the firstline setting (Tab. I).
ECOG 2100
The ECOG 2100 trial compared the efficacy and safety of weekly paclitaxel plus bevacizumab with paclitaxel alone in 722 patients with MBC (18) . The primary endpoint of the study was PFS. Patients were randomly assigned to receive weekly paclitaxel (90 mg/m 2 ) on days 1, 8, and 15 every 28 days either alone or in combination with bevacizumab (10 mg/kg) on days 1 and 15. Patients continued therapy in the absence of disease progression or prohibitive toxicity. Median PFS was 11.8 months for the combination of paclitaxel/ bevacizumab were also validated by an independent review (21) . The combination of bevacizumab with weekly paclitaxel proved a tolerable regimen, with similar low rates of hematologic, gastrointestinal, and musculoskeletal adverse events in each group. Rates of grade 3 or 4 neuropathy (23.6% vs 17.6%; p = 0.03), infection (9.3% vs 2.9%; p<0.001), and fatigue (8.5% vs 4.9%; p = 0.04) were higher in the combination group. versus 5.9 months for paclitaxel alone (hazard ratio [HR] 0.6; p<0.001). Overall, adding bevacizumab to paclitaxel significantly improved the objective response rate (ORR) (36.9% vs 21.2%; p<0.001). Combined therapy increased the 1year survival rate (81.2% vs 73.4%; p = 0.01); however, the median overall survival (OS) rate (26.7 vs 25.2 months, HR 0.88; p = 0.16) was similar between the 2 groups. These results Grade 34 hypertension was more common in patients receiving bevacizumab (14.8% vs 0%; p<0.001). Proteinuria was also more common in the experimental arm, but was rarely clinically significant (grade 3 proteinuria 2.7% vs 0%, respectively; p<0.001). No differences in quality of life were observed between the 2 groups. Interestingly, an exploratory analysis of the ECOG 2100 data showed that patients who had received prior taxanebased adjuvant therapy also benefitted from the addition of bevacizumab (18) .
AVADO
The AVADO (Avastin and docetaxel) trial, a randomized, doubleblind, placebocontrolled trial, investigated the efficacy of docetaxel alone or with bevacizumab at a dose of 7.5 or 15 mg/kg as firstline therapy in patients with HER2 negative MBC (22) . The primary endpoint was PFS. This study, however, was not designed to detect a statistically significant difference between bevacizumab doses. Patients (n = 736) were randomized to either docetaxel (100 mg/m 2 ) every 21 days with bevacizumab at a dose of 7.5 mg/kg or 15 mg/ kg or docetaxel with placebo, for a maximum of 9 cycles of docetaxel. Earlier discontinuation was allowed for drug intolerability. Two dose reductions, to 75 mg/m 2 and/or 60 mg/ m 2 , were also allowed. Continuation on bevacizumab or placebo as maintenance therapy until disease progression was permitted following discontinuation of docetaxel. The majority of patients (75%) had received prior anthracycline and/ or taxanebased adjuvant chemotherapy. After progression, all patients were given the option to receive bevacizumab in combination with secondline regimens. The association of bevacizumab with docetaxel showed superior PFS compared to placebo plus docetaxel, at both 7.5 mg/kg (9.0 vs 8.1 months, stratified HR 0.8; p = 0.045) and 15 mg/kg (10.0 vs 8.1 months, stratified HR 0.67; p<0.001). Both doses of bevacizumab were also associated with significantly higher ORRs (7.5 mg/kg: 55.2% vs 46.4%; p = 0.07; 15 mg/kg: 64.1% vs 46.4%; p<0.001). However, as in the ECOG 2100 study, the rate of OS was similar across all 3 arms, with median values of 31 months (HR 1.05; p = 0.72 for bevacizumab at 7.5 mg/kg; HR 1.03; p = 0.85 for bevacizumab at 15 mg/kg). The addition of bevacizumab to docetaxel had limited impact on the known toxicity profile of docetaxel.
RIBBON-1
The Regimens in Bevacizumab for Breast Oncology (RIB-BON)1 trial was an international, multicenter, phase III, placebocontrolled trial. Patients (n = 1,237) were randomly assigned 2:1 to receive either chemotherapy (capecitabine, taxanebased, or anthracyclinebased chemotherapy) plus bevacizumab or chemotherapy plus placebo, as firstline treatment for HER2negative MBC (23) . The primary endpoint was PFS. Secondary endpoints included ORR, OS, and 1year survival rate. The combination of bevacizumab and chemotherapy as firstline therapy resulted in a statistically significant improvement in PFS. In the taxane or anthracycline cohort, median PFS resulted in 9.2 versus 8.0 months (HR 0.64; 95% confidence interval [CI] 0.520.80; p<0.001). Similarly, capecitabine plus bevacizumab significantly improved PFS compared with capecitabine alone (8.6 vs 5.7 months; HR 0.69; CI 0.560.84; p<0.001). However, there was no statistically significant improvement in OS or the 1year survival rate between treatment arms for either cohort. For the cohort of patients who received capecitabine, the estimated HR for OS was 0.85 (95% CI 0.631.14; p = 0.27), and there was a trend for improved 1year survival in the bevacizumabcontaining arm (81.0% vs 74.4%; p = 0.076). For patients who received anthracyclines or taxanes (with or without bevacizumab), the stratified HR for OS was 1.03 (95% CI 0.771.38; logrank p = 0.83), and the 1year survival rate was 83.2% versus 80.7% (p = 0.44).
Meta-analyses show improved PFS but not OS
A metaanalysis performed by Miles et al (24) (n = 2,447) determined that bevacizumab increased PFS compared with nonbevacizumab therapy (HR 0.64, 95% CI 0.570.71; median PFS 9.2 months vs 6.7 months) and also improved the ORR (49% vs 32%). However, there was no significant difference in OS between the bevacizumab and nonbevacizumab cohorts (HR 0.97, 95% CI 0.86-1.08; median OS 26.7 vs 26.4 months).
Oneyear survival rate was significantly increased in the bevacizumab arms (77% vs 82%; p = 0.003). Furthermore, bevacizumab in poorprognosis patients with triplenegative MBC prolonged PFS (HR 0.63; 95% CI 0.520.76) without statistically significant improvement in OS (HR 0.96; 95% CI 0.791.16). The median PFS was 8.1 months with bevacizumab versus 5.4 months with chemotherapy alone, while the median OS was 18.9 versus 17.5 months, and the 1year OS rates were 71% versus 65%.
These results were similar to those of previously published metaanalyses that evaluated the efficacy of bevacizumab in combination with chemotherapy for the firstline treatment of MBC. A metaanalysis by Valachis et al (25) pooled data from the 3 randomized studies E2100, AVADO, and RIBBON1, a phase II study, and a trial with bevacizumab after firstline chemotherapy for MBC, and found that the addition of bevacizumab firstline MBC significantly improved PFS, with a global HR of 0.70 (95% CI 0.600.82; p<0.001). This benefit in PFS was seen across different subgroups and independently from sites of metastases, hormone receptor status, or prior adjuvant taxane treatment. The addition of bevacizumab to chemotherapy was also related to a significant improvement in ORR (p<0.001). However, no significant increases in OS were observed in the bevacizumabcontaining arms, with a global HR of 0.90 (95% CI 0.801.03; p = 0.119).
Lee et al (26) evaluated 4 studies involving a total of 2,860 patients and reported improvement in PFS for patients treated in bevacizumabcontaining arms (pooled HR 0.69, 95% CI 0.580.81), but not OS (HR 0.92, 95% CI 0.821.03) or ORR (HR 1.53, 95% CI 1.37-1.71).
Rossari et al (27) performed a metaanalysis on the E2100, AVADO, and RIBBON1 studies. They found that adding bevacizumab to chemotherapy in the firstline treatment of MBC significantly improved PFS, with an overall HR of 0.70 (95% CI 0.570.86; p = 0.0006). The PFS was assessed according to hormone receptor status (positive or negative), prior adjuvant chemotherapy (yes or no), age (<65 years vs ≥65 years), prior use of taxanes (yes or no), and disease-free interval (DFI) (short vs long). It was noted that the analysis by DFI was different among the trials, with the AVADO and E2100 trials stratifying DFI by ≤24 months versus >24 months, whereas RIBBON1 stratified by ≤12 months versus >12 months. However, adding bevacizumab to chemotherapy provided a consistent benefit in PFS in all the patient subgroups analyzed. Nevertheless, none of the individual studies showed a significant OS benefit of combining bevacizumab with chemotherapy and, globally, no statistically significant OS benefit (HR 0.95, 95% CI 0.85 to 1.06; p = 0.65) was reported.
ATHENA real-world study
ATHENA was an openlabel, singlearm, international study conducted in a realworld oncology practice setting and included a total of 2,251 patients with MBC who received first line therapy with bevacizumab plus taxane monotherapy or combination chemotherapy. ATHENA was the largest study of patients with MBC treated with bevacizumabcontaining chemotherapy regimens to be carried out in a broad community based population (28) more closely representative of routine clinical oncology practice. The primary objective was safety. Secondary endpoints were time to progression (TTP) and OS.
Patients in this study received, at the discretion of treating oncologists, bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks plus taxanebased chemotherapy or other non anthracycline regimen until disease progression, unacceptable toxicity, or patient withdrawal (28) . The majority of patients had primarily estrogen receptorpositive BC (66.1%) and more than 3 metastatic sites (64%). Chemotherapeutic agents more frequently combined with bevacizumab were singleagent paclitaxel (35%) or docetaxel (33%). The paclitaxel administration was weekly in 17% of cases, versus 13% every 3 weeks or other schedule in 6%. A further 10% of patients received taxane based combination regimens, commonly with carboplatin and gemcitabine. The nontaxane chemotherapies most frequently utilized were capecitabine (5%) and vinorelbine (3%). The median treatment duration of treatment was 6.2 months for bevacizumab (range 0.029.7) and 4.2 months for chemotherapy (range 0.0-29.5).
Safety and efficacy data were consistent with the findings of the previous reported randomized clinical trials of chemotherapy evaluating bevacizumab in combination with first line taxanebased regimens for locally recurrent BC or MBC. Firstline bevacizumab in combination with taxanebased chemotherapy was welltolerated, with a low incidence of severe adverse events (SAEs) or specific adverse events (AEs) in a broad population of BC patients (28) . The most frequent SAEs were febrile neutropenia (5.1%), neutropenia (3.6%), and pyrexia (1.5%). The incidence of grade 34 hypertension was 4.4%, lower than that reported in E2100 (16%), but similar to AVADO (4.5%). Furthermore, other bevacizumab related SAEs of grade 3 or higher were uncommon and consisted of arterial/venous thromboembolism (3.3%), proteinuria (1.7%), gastrointestinal perforation (0.26%), and congestive heart failure (0.44%). The overall median TTP was 9.5 months (95% CI 9.19.9). The ORR in the intenttotreat (ITT) population was 52% and a further 33% of patients achieved disease stabilization as their best response.
Final survival data from the ATHENA study after a median followup duration of 20.1 months showed that OS was 25.2 months in patients receiving bevacizumab in combination with standard firstline chemotherapy (29) . Furthermore, for patients who continued bevacizumab monotherapy after stopping chemotherapy, median TTP was 11.6 months and median OS 30.0 months (29) .
Interestingly, a subanalysis in the elderly subpopulation of the ATHENA study was published, comprising 175 patients aged ≥70 years (30) . Approximately half of these patients (46%) received a paclitaxel regimen in combination with bevacizumab. The combination was welltolerated by elderly patients. The median TTP in this subpopulation was 10.4 months (95% CI 8.811.8 months), compared with 9.5 months (95% CI 9.19.9) in the overall ITT population. The ORR was 42% for the elderly patients, compared with 52% in the overall ITT population. Final survival data in this patient group showed a median OS of 20.4 months. Moreover, the overall incidence of bevacizumabrelated SAEs was similar to that reported in younger patients (<70 years). The only grade ≥3 SAEs more commonly reported in older versus younger patients were hypertension (6.9% vs 4.2%) and proteinuria (4.0% vs 1.5%). The incidences of grade 3 or higher arterial/venous thromboembolic events (2.9%vs 3.3%), CNS hemorrhage (<0.1%), and cardiac events (0.6 vs 0.4%) were similar to younger patients.
Efficacy of bevacizumab plus paclitaxel
A recent study confirmed that the addition of bevacizumab to a paclitaxelbased regimen was an active and welltolerated firstline treatment for MBC (31) . In 220 patients with previously untreated MBC, the combination of bevacizumab plus paclitaxel resulted in a median PFS of 9.3 months (95% CI 7.8-10.8) and a 1-year survival rate of 68%. This regimen also presented notable activity in patients with triplenegative BC (TNBC; n = 106) with a median PFS of 8.3 months (95% CI 7.88.8). Severe AEs were consistent with the established safety profile of bevacizumab plus paclitaxel.
Discussion
The combination of bevacizumab with taxanebased regimens has been associated with benefits in ORR and PFS in the firstline treatment of patients with locally recurrent BC or MBC (32) . However, to date, no significant OS advantage has been observed in randomized clinical trials. The RIBBON2 study showed a trend towards a benefit in OS with bevacizumab, even though the benefit in OS was not statistically significant (33) . The openlabel, singlearm, international, realworld ATHENA trial also reported a notable OS in patients receiving bevacizumab in combination with standard firstline chemotherapy, also including elderly population, and, above all, for patients who received maintenance with bevacizumab monotherapy after stopping chemotherapy (29) . The RIB-BON2 trial only included pretreated patients, and ATHENA was in patients not previously treated for metastatic disease. Although the benefit was persistent in the TNBC and elderly subgroups, no clear benefit on OS was demonstrated (30, 34) . Furthermore, the singlearm ATHENA trial does not allow us to define the impact of the addition of bevacizumab to chemotherapy. Nevertheless, its large sample size (n = 2,251) could provide valuable information on outcomes in clinically important subgroups, including patients with TNBC and the elderly. The results of a multicenter national French observational study, based on a largescale reallife setting database, the Epidemiological Strategy and Medical Economics program, were presented at the recent American Society of Clinical Oncology annual meeting (35) . Significantly better OS was reported in the 2,127 patients with HER2negative MBC who received paclitaxel plus bevacizumab, compared with the 1,299 patients receiving paclitaxel alone (HR 0.672 [95% CI 0.601, 0.752]; median survival time, 27.7 vs 19.8 months). Also, PFS was better for patients receiving paclitaxel plus bevacizumab versus paclitaxel (HR 0.739 [0.672, 0.813]; 8.1 vs 6.4 months). All data were consistent across all supportive and sensitivity analyses, as well as in triplenegative and estrogen receptorpositive subgroups. Concerning this, it is worth noting that a robust methodology was applied. However, as the same authors concluded, despite the robust methodology, realworld data should be interpreted with caution.
To be thorough, no benefits were reported in patients with earlier stage BC with the addition of bevacizumab in the adjuvant setting (36, 37) . However, this is not a subject of this review.
In MBC, due to the lack of a clear survival benefit associated with bevacizumab, the FDA recommended against bevacizumab in 2010 (19, 20) . The FDA revocation resulted from concerns about safety, considering that bevacizumab did not improve OS in different randomized studies.
One of the major problems has been its lack of an OS benefit. However, there is no unanimous opinion on the appropriateness of OS as a sole primary endpoint in firstline MBC clinical trials, which has been the subject of lively debate. Interestingly, Cortés et al (38) reported that, even though from a regulatory standpoint gain in OS is the gold standard for drug approval, PFS could be a valid surrogate endpoint in some diseases and in specific treatment settings.
The value of PFS in the context of MBC remains controversial. However, PFS has several important advantages in MBC trials. To date, patients with MBC usually receive multiple lines of subsequent therapy (Tab. II), and PFS/TTP should be considered true endpoints since they are not affected by subsequent lines of chemotherapy. In MBC, a strikingly small proportion of all trials (12%), and even fewer firstline trials (4.8%), demonstrated OS gain. According to the model proposed by Broglio and Berry (39) on postprogression survival (PPS), OS would be an appropriate primary endpoint when there is a short median PPS interval. On the other hand, when the PPS is >12 months, subsequent lines of chemotherapy would dilute the effect of the study medication on OS. In MBC, the ability of firstline phase III trials to demonstrate a treatment effect upon OS depends on the duration of PPS (40, 41) . Indeed, OS may be a more appropriate endpoint for second or thirdline trials, when PPS is shorter. This is illustrated by the recent EMBRACE trial in heavily pretreated patients with anthracycline and taxanerefractory MBC who were randomized to monotherapy with the microtubule inhibitor eribulin or treatment of physician's choice. Eribulin significantly improved OS (median 13.1 months, 95% CI 11.8 14.
3) compared with the reallife standard treatment choices (10.6 months, 95% CI 9.3-12.5; HR 0.81, 95% CI 0.66-0.99; p = 0.041) (42) .
Moreover, these clinical trials did not collect data on post progression therapies. Without details on subsequent treatments, it would be impossible to determine the impact of different posttrial therapies patients received in the bevacizumab and nonbevacizumab arms. Furthermore, the lack of statistically significant OS benefit could be due to the cross over to bevacizumab allowed to patients in nonbevacizumab arms at the time of progression (22, 23) .
Several issues arise over the FDA's removal of the BC indication for bevacizumab. If this decision was based on a lack of OS benefit, it is unclear why the indications for bevacizumab in other cancers remain, particularly as a clear OS survival benefit has not been established for the majority of cytotoxic chemotherapy combinations in current use in MBC. Even the most wellestablished cytotoxic regimens show at best only marginally significant OS benefits (43, 44) , which makes the FDA's decision appear at least controversial, if not arbitrary.
The FDA cited primarily safety-related concerns for its reasons to remove the MBC indication for bevacizumab (45) . These toxicities include hypertension, proteinuria, thrombosis, and hemorrhage (46) . However, as previously reported in available MBC phase III safety data (AVF2119g, E2100, AVADO, RIBBON1, and RIBBON2), bevacizumab generally appeared to be welltolerated (18, 22, 23, 33, 47) . Typically, SAEs occurring during treatment with bevacizumab are predictable, mild to moderate in severity, and/or manageable with standard medication, and usually do not necessitate discontinuation of therapy. In general, bevacizumab has been shown to have a favorable tolerability profile when used in various combination therapy approaches, including in special populations such as the elderly and patients with poor performance status (48) . However, AEs such as arterial thrombosis and cardiac toxicity, although uncommon with bevacizumab, are more serious and require appropriate clinical awareness and prudent monitoring.
Regarding cost, bevacizumab seems expensive and not costeffective as a firstline treatment for MBC. The costeffectiveness of bevacizumab in combination with paclitaxelbased chemotherapy has been assessed using a (52, 53) or the most expensive drugs employed in other cancer types, for example trabectedin in ovarian cancer (54, 55) . Nevertheless, physicians who have access to expensive interventions have a responsibility to consider the costeffectiveness of cancer drugs as part of their role as overseers of finite health care resources (56, 57) . Taking into consideration very limited healthcare budgets, alternative solutions such as risksharing schemes should be considered. To this end, risksharing schemes for pharmaceuticals can be regarded as agreements between payers and pharmaceutical companies with the aim of reducing the impact of new and existing medicines on the payer's budget where there is uncertainty regarding the value of the medicine and/or the need to work within finite budgets. Strategies to accelerate reimbursement and improve access for newer and potentially innovative medicines, particularly where limited data are available at the time of marketing approval, have recently been initiated by the Italian Medicines Agency (AIFA), using 2 different approaches: variations on patient access schemes and performancebased/outcome contracts (where the pharmaceutical company reimburses the cost if the medicine is shown to be ineffective and the National Health Service pays for effective medicines) (5860). The AIFA Oncologic Working Group proposed 2 risksharing arrangements for new anticancer drugs to enhance their reimbursement potential according to the following criteria: "epidemiological data for the disease; the possibility of clearly defining a subset of the population responsive to the treatment; and results from clinical trials" (60) . Bevacizumab-for metastatic carcinoma of the colon or rectum, BC, nonsmall cell lung cancer, and advanced and/or metastatic renal cell cancer-was included in this scheme.
Conclusion
The addition of bevacizumab to chemotherapy has produced substantial improvements in ORR and PFS, compared with chemotherapy alone, in advanced HER2negative BC. However, no significant OS improvement has been observed so far, and further followup is needed. Still to be answered from currently available and emerging data is whether prolongation of PFS is in itself enough to consider bevacizumab efficacious in MBC. Moreover, it should be noted that bevacizumab was welltolerated in studies in patients with MBC, and AEs were fairly manageable, with remarkably similar frequencies of bevacizumabrelated AEs when combined with a number of different anticancer drugs. Patients with TNBC seem particularly wellsuited to bevacizumab treatment. Finally, the cost of treatment with bevacizumab is consistent with the costs of other generally accepted new anticancer treatments, and should therefore not be considered a deterrent to its use in MBC.
To date, there is no role for bevacizumab for the treatment of earlystage BC. On the other hand, bevacizumab, based on the available clinical trials results, is a part of the complex therapeutic context of MBC. The identification of biomarkers would be useful to optimize its use in MBC.
